Page 6 - Pharma Services News Today

NeoGenomics (NASDAQ:NEO – Free Report) had its target price cut by TD Cowen from $22.00 to $19.00 in a research note released on Friday morning, Benzinga reports. They currently have an outperform rating on the medical research company’s stock. A number of other research analysts have also recently commented on NEO. Morgan Stanley upped their […]

Needham & Company LLC reiterated their buy rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. The brokerage currently has a $21.00 price target on the medical research company’s stock. Other equities research analysts also recently issued research reports about the company. StockNews.com […]

NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $20.50, but opened at $18.05. NeoGenomics shares last traded at $17.43, with a volume of 713,161 shares traded. Wall Street Analyst Weigh In A number of research analysts have recently weighed in […]

NeoGenomics (NASDAQ:NEO – Get Free Report) and Applied DNA Sciences (NASDAQ:APDN – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations. Earnings & Valuation This table compares NeoGenomics and […]

NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) has earned an average rating of “Moderate Buy” from the eleven analysts that are presently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among analysts […]

Graeme Daniels, PhD, has been appointed as the new Vice President of Sales and Marketing by Sphere Fluidics, a leading provider of microfluidics-based solutions for single-cell analysis and isolation. Click to read more...

Shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $20.75 and last traded at $20.55, with a volume of 845796 shares traded. The stock had previously closed at $19.24. Analysts Set New Price Targets Several equities research analysts […]

/PRNewswire/ -- The "Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2024-2034" report has been added to...

NeoGenomics (NASDAQ:NEO – Get Free Report) and Applied DNA Sciences (NASDAQ:APDN – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends. Valuation and Earnings This table compares NeoGenomics and […]

Appointment to senior leadership team strengthens the Company’s plans for continued growth to advance its commercial ambitions.